Valeant Pays $12M To Settle Wellbutrin Antitrust Claims

By Daniel Wilson (February 15, 2013, 7:14 PM EST) -- Valeant Pharmaceuticals International Inc. will pay at least $11.75 million to settle a class action brought by health insurers and other indirect purchasers, accusing it of conspiring to stifle generic versions of antidepressant Wellbutrin XL and monopolize the market, according to documents filed Friday in Pennsylvania federal court....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.

A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!